CC-90001

Drug Celgene Corporation
Total Payments
$2.3M
Transactions
180
Doctors
32
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2019 $1.3M 134 27
2018 $792,692 30 8
2017 $162,033 16 4

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $2.2M 101 99.1%
Travel and Lodging $16,510 54 0.7%
Food and Beverage $4,774 24 0.2%
Education $10.51 1 0.0%

Payments by Type

Research
$2.2M
101 transactions
General
$21,294
79 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
A study to evaluate the efficacy and safety of CC-90001 in subjects with idiopathic pulmonary fibrosis (CC-90001-CP-005) Celgene Corporation $809,900 0
CC-90001-CP-004 - A Phase 1, Open-Label, Fixed-Sequence Study in Healthy Subjects to Assess the Effects of CC-90001 on the Pharmacokinetics of Substrates for Cytochrome P450 isoforms as well as efflux and uptake transp Celgene Corporation $498,182 0
CC-90001-IPF-001 - IPF-001 Phase 2 (CC-90001-IPF-001) (BMS Study Number: IM043-P04) Celgene Corporation $294,446 5
IPF-001 Phase 2 (CC-90001-IPF-001) (BMS Study Number: IM043-P04) (CC-90001-IPF-001) Celgene Corporation $274,858 5
A Phase 1, Open-Label, Fixed-Sequence Study in Healthy Subjects to Assess the Effects of CC-90001 on the Pharmacokinetics of Substrates for Cytochrome P450 isoforms as well as efflux and uptake transporters (CC-90001-CP-004) Celgene Corporation $112,556 0
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Finding Study To Evaluate The Efficacy and Safety Of CC-90001 In Subjects With Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis (CC-90001-NASH-001) Celgene Corporation $94,125 1
CC-90001-CP-003 Celgene Corporation $88,698 0
CC-90001-IPF-001 Celgene Corporation $58,134 4
CC-90001-CP-004 Celgene Corporation $15,201 0

Top Doctors Receiving Payments for CC-90001

Doctor Specialty Location Total Records
Unknown — Denver, CO $2.2M 86
, MD Diagnostic Radiology Seattle, WA $18,900 3
, M.D Diagnostic Radiology Madison, WI $17,500 3
, M.D Anatomic Pathology Scottsdale, AZ $5,400 3
, M.D Anatomic Pathology & Clinical Pathology Scottsdale, AZ $2,200 2
, M.D Internal Medicine New York, NY $1,845 4
, MD Critical Care Medicine New Haven, CT $1,800 1
, M.D Gastroenterology Saint Louis, MO $1,356 4
, MD Hepatology Kansas City, MO $1,305 4
, MD Gastroenterology Tampa, FL $1,293 4
, M.D Internal Medicine Los Angeles, CA $1,200 1
, M.D Gastroenterology Memphis, TN $1,162 3
, M.D Gastroenterology Burlington, VT $1,138 3
, MD, MBBS Gastroenterology Richmond, VA $965.54 3
, MD Internal Medicine Chattanooga, TN $936.39 4
, MD Internal Medicine New York, NY $905.29 4
, MD Hepatology New Orleans, LA $877.95 3
, MD Gastroenterology Chicago, IL $876.05 3
, MD, MPH Internal Medicine New Haven, CT $872.20 4
, M.D Internal Medicine Richmond, VA $848.45 3
, MD Internal Medicine Chapel Hill, NC $835.72 3
, MD Gastroenterology New York, NY $834.06 3
, M.D Gastroenterology Englewood, CO $804.84 4
, D.O Internal Medicine Rochester, NY $799.45 3
, M.D Gastroenterology Catonsville, MD $774.29 4
12»

Manufacturing Companies

Product Information

  • Type Drug
  • Total Payments $2.3M
  • Total Doctors 32
  • Transactions 180

About CC-90001

CC-90001 is a drug associated with $2.3M in payments to 32 healthcare providers, recorded across 180 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.

Payment data is available from 2017 to 2019. In 2019, $1.3M was paid across 134 transactions to 27 doctors.

The most common payment nature for CC-90001 is "Unspecified" ($2.2M, 99.1% of total).

CC-90001 is associated with 9 research studies, including "A study to evaluate the efficacy and safety of CC-90001 in subjects with idiopathic pulmonary fibrosis (CC-90001-CP-005)" ($809,900).